Tilray Brands Sees 5% Boost in Q2 Cannabis Revenue

Tilray Brands reported a 5% increase in cannabis revenue for its fiscal second quarter, reaching $218 million, driven by strong international medical sales and growth in the Canadian adult-use market.

The company also announced it has achieved a net cash position—meaning more cash on hand than debt—a significant milestone in an industry where most operators carry substantial debt burdens.

CEO Irwin Simon said Tilray is "well-positioned to capitalize on emerging opportunities," particularly anticipated cannabis rescheduling in the United States.

Revenue Drivers

International medical cannabis sales jumped 36% year-over-year, reflecting Tilray's expansion in European markets including Germany and Portugal. The company supplies medical cannabis to patients through partnerships with pharmacies and healthcare systems.

Canadian adult-use cannabis revenue grew 6%, indicating Tilray is gaining market share in the competitive domestic market. The company operates retail stores under the High Park and Chowie Wowie brands, plus wholesale operations selling to other retailers.

Tilray Pharma, the company's pharmaceutical division, also achieved record quarterly revenue—though specific figures weren't disclosed.

Cash Position

Moving to a net cash position gives Tilray more financial flexibility than most cannabis operators. The company can fund expansion, acquisitions, or product development without taking on additional debt or facing pressure from lenders.

This contrasts sharply with many cannabis companies that have restructured debt, diluted shareholders, or sold assets to manage cash flow challenges amid falling prices and slower growth.

Tilray maintained its full-year adjusted EBITDA guidance despite industry headwinds, suggesting confidence in continued performance.

U.S. Opportunities

Tilray currently doesn't operate in the U.S. THC market due to Nasdaq listing rules that prohibit companies from touching federally illegal substances. But cannabis rescheduling could change that.

If marijuana moves to Schedule III, Nasdaq restrictions might ease—allowing Tilray to enter U.S. cannabis through acquisitions or new operations. The company has made clear it's ready to move into the U.S. market if regulatory barriers fall.

For now, Tilray focuses on CBD products in the United States while building its international cannabis business and non-cannabis beverage operations.

---

This article is based on original reporting by New Cannabis Ventures.